113 related articles for article (PubMed ID: 30583927)
1. Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?
Sabbagh A; Jacobs C; Cooke R; Chu KY; Ng SM; Strauss VY; Virdee PS; Hawkins MA; Aznar MC; Muirhead R
Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):72-80. PubMed ID: 30583927
[TBL] [Abstract][Full Text] [Related]
2. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
3. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
4. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial.
Jones MP; Hruby G; Metser U; Sridharan S; Capp A; Kumar M; Gallagher S; Rutherford N; Holder C; Oldmeadow C; Martin J
Radiat Oncol; 2019 Aug; 14(1):140. PubMed ID: 31387597
[TBL] [Abstract][Full Text] [Related]
6. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma.
Duimering A; Riauka T; Nijjar Y; Ghosh S; MacEwan R; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Nijjar T; Fairchild A; Mulder K; Doll C; Wong C; Joseph K
Radiother Oncol; 2019 Jul; 136():21-28. PubMed ID: 31015125
[TBL] [Abstract][Full Text] [Related]
8. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
9. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Wilson JM; Mukherjee S; Chu KY; Brunner TB; Partridge M; Hawkins M
Radiat Oncol; 2014 Jun; 9():146. PubMed ID: 24962658
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
Palie O; Michel P; Ménard JF; Rousseau C; Rio E; Bridji B; Benyoucef A; Meyer ME; Jalali K; Bardet S; M'vondo CM; Olivier P; Faure G; Itti E; Diana C; Houzard C; Mornex F; Di Fiore F; Vera P
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1345-55. PubMed ID: 23715903
[TBL] [Abstract][Full Text] [Related]
11. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
[TBL] [Abstract][Full Text] [Related]
12. Role of 18F-FDG PET-derived parameters for predicting complete response to chemoradiotherapy in squamous cell anal carcinoma.
Filippi L; Fontana A; Spinelli GP; Rossi L; Bagni O
Nucl Med Commun; 2020 Oct; 41(10):1089-1094. PubMed ID: 32732599
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
14. Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.
Teng F; Aryal M; Lee J; Lee C; Shen X; Hawkins PG; Mierzwa M; Eisbruch A; Cao Y
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):969-977. PubMed ID: 29428251
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
[TBL] [Abstract][Full Text] [Related]
16. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Shusharina N; Cho J; Sharp GC; Choi NC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):137-44. PubMed ID: 24725696
[TBL] [Abstract][Full Text] [Related]
17. Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions.
Aristophanous M; Yap JT; Killoran JH; Chen AB; Berbeco RI
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):900-8. PubMed ID: 20950956
[TBL] [Abstract][Full Text] [Related]
18. A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
La Fontaine M; Vogel W; van Diessen J; van Elmpt W; Reymen B; Persson G; Westman G; De Ruysscher D; Belderbos J; Sonke JJ
Radiother Oncol; 2018 May; 127(2):259-266. PubMed ID: 29709378
[TBL] [Abstract][Full Text] [Related]
19. Correlation of
Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
[TBL] [Abstract][Full Text] [Related]
20. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
